Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
Active, not recruiting
Celgene Corporation
Phase 3
2009-10-01
The purpose of this study is to determine the safety and efficacy of lenalidomide as a first
line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will
compare the effects (good and bad) of lenalidomide with chlorambucil.
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chron
Completed
Gilead Sciences
Phase 1
2010-04-01
This study will evaluate the safety and clinical activity of idelalisib in combination with
an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, an mTOR inhibitor, a
protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in
participants with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle
cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL).
Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia
Unknown status
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3
2011-01-01
The purpose of this study is to determine whether bendamustine is effective in the treatment
of initial treatment of Chronic Lymphocytic Leukemia (CLL).
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment
Recruiting
Chugai Pharma USA
Phase 3
2011-12-01
The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab
& bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not
fit enough for rituximab, fludarabine & cyclophosphamide (R-FC).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
